Pathstone Holdings’s Exact Sciences EXAS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-17,046
Closed -$1.73M 2266
2025
Q4
$1.73M Sell
17,046
-230
-1% -$18.5K 0.01% 1104
2025
Q3
$945K Buy
17,276
+1,151
+7% +$57.5K ﹤0.01% 1458
2025
Q2
$857K Buy
16,125
+5,736
+55% +$291K ﹤0.01% 1468
2025
Q1
$450K Buy
10,389
+388
+4% +$19.6K ﹤0.01% 1766
2024
Q4
$562K Sell
10,001
-870
-8% -$54.1K ﹤0.01% 1673
2024
Q3
$741K Buy
10,871
+3,708
+52% +$209K ﹤0.01% 1523
2024
Q2
$303K Sell
7,163
-2,918
-29% -$161K ﹤0.01% 1934
2024
Q1
$696K Buy
10,081
+1,689
+20% +$107K ﹤0.01% 1517
2023
Q4
$621K Buy
+8,392
New +$550K ﹤0.01% 1373

Other funds holding EXAS

Pathstone Holdings's EXAS Position: Q1 2026 in Review

Pathstone Holdings sold out of Exact Sciences (EXAS) in Q1 2026, closing a stake of 17,046 shares — an estimated $1.73M sold.

Pathstone Holdings first reported a position in EXAS in Q4 2023 and held it in 9 quarters. The position peaked at $1.73M in Q4 2025. 7 funds tracked by Wall St. Rank hold EXAS as of Q1 2026.

  • Pathstone Holdings reported no remaining Exact Sciences position as of Q1 2026 after selling out during the quarter.
  • Pathstone Holdings sold 17,046 Exact Sciences shares in Q1 2026, an estimated $1.73M.
  • Pathstone Holdings first reported a position in Exact Sciences in Q4 2023 and held it in 9 quarters.
  • Pathstone Holdings's Exact Sciences position peaked at $1.73M in Q4 2025.
  • 7 funds tracked by Wall St. Rank held Exact Sciences as of Q1 2026.

Based on Pathstone Holdings's 13F filing for Q1 2026, filed 11 May 2026.